Brokers Issue Forecasts for Inspire Medical Systems, Inc.’s FY2027 Earnings (NYSE:INSP)

Inspire Medical Systems, Inc. (NYSE:INSP) – Leerink Partnrs upped their FY2027 earnings estimates for Inspire Medical Systems in a note issued to investors on Tuesday, May 7th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn $4.15 per share for the year, up from their prior estimate of $4.13. The consensus estimate for Inspire Medical Systems’ current full-year earnings is ($0.35) per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ FY2028 earnings at $5.21 EPS.

Other equities analysts also recently issued reports about the stock. Morgan Stanley started coverage on shares of Inspire Medical Systems in a research note on Tuesday, March 19th. They set an “overweight” rating and a $250.00 price objective on the stock. Jefferies Financial Group initiated coverage on Inspire Medical Systems in a research note on Friday, January 19th. They issued a “buy” rating and a $245.00 target price on the stock. KeyCorp started coverage on shares of Inspire Medical Systems in a research report on Tuesday, February 6th. They set an “overweight” rating and a $278.00 price target for the company. Bank of America lowered shares of Inspire Medical Systems from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $265.00 to $225.00 in a research note on Wednesday. Finally, Piper Sandler raised their target price on shares of Inspire Medical Systems from $250.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.53.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $174.36 on Thursday. Inspire Medical Systems has a one year low of $123.27 and a one year high of $330.00. The company has a market capitalization of $5.28 billion, a price-to-earnings ratio of -317.02 and a beta of 1.35. The company’s 50-day simple moving average is $215.59 and its two-hundred day simple moving average is $190.27.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.29. The company had revenue of $164.01 million for the quarter, compared to the consensus estimate of $161.41 million. Inspire Medical Systems had a negative return on equity of 3.93% and a negative net margin of 3.39%. Inspire Medical Systems’s quarterly revenue was up 28.2% on a year-over-year basis. During the same period last year, the business posted ($0.53) EPS.

Institutional Trading of Inspire Medical Systems

A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC grew its stake in Inspire Medical Systems by 130.1% in the 3rd quarter. FMR LLC now owns 2,471,464 shares of the company’s stock valued at $490,437,000 after acquiring an additional 1,397,510 shares during the period. Baillie Gifford & Co. boosted its stake in Inspire Medical Systems by 19.3% during the 1st quarter. Baillie Gifford & Co. now owns 1,467,613 shares of the company’s stock worth $315,229,000 after purchasing an additional 237,734 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Inspire Medical Systems by 46.4% during the fourth quarter. Wellington Management Group LLP now owns 1,430,266 shares of the company’s stock worth $290,959,000 after buying an additional 453,294 shares in the last quarter. Wasatch Advisors LP raised its position in shares of Inspire Medical Systems by 0.5% in the first quarter. Wasatch Advisors LP now owns 1,102,867 shares of the company’s stock valued at $236,885,000 after buying an additional 5,522 shares during the last quarter. Finally, Frontier Capital Management Co. LLC lifted its stake in shares of Inspire Medical Systems by 105.2% in the fourth quarter. Frontier Capital Management Co. LLC now owns 742,046 shares of the company’s stock worth $150,954,000 after buying an additional 380,362 shares in the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, CEO Timothy P. Herbert sold 40,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $205.09, for a total value of $8,203,600.00. Following the sale, the chief executive officer now directly owns 63,658 shares of the company’s stock, valued at $13,055,619.22. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Timothy P. Herbert sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $205.09, for a total transaction of $8,203,600.00. Following the sale, the chief executive officer now owns 63,658 shares of the company’s stock, valued at approximately $13,055,619.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Richard Buchholz sold 15,000 shares of Inspire Medical Systems stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $230.03, for a total transaction of $3,450,450.00. Following the transaction, the chief financial officer now directly owns 28,271 shares of the company’s stock, valued at $6,503,178.13. The disclosure for this sale can be found here. Insiders have sold 76,371 shares of company stock worth $15,664,278 over the last 90 days. 4.10% of the stock is currently owned by company insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.